Carolyn Westhoff

The introduction of oral GnRH antagonists has created the possibility to replace progestins in combined oral contraceptives as the suppressor of ovarian function. A concept for this new approach to oral hormonal contraception is the combina…

ObjectivesTo describe ovulation inhibition and safety of daily oral ulipristal acetate (UPA) over 84 days.Study designThis multi-center phase 1 and/or 2 trial randomized participants to use oral ulipristal 10 mg or 5 mg daily or a 3 cycle r…

INTRODUCTION: Real-world data on the use of elagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in combination with hormonal contraceptives (HC) is limited. This analysis evaluated endometriosis-associated pain in w…

BACKGROUND: Although studies have found elevated risks of certain cancers linked to infertility, the underlying reasons remain unclear. METHODS: In a retrospective cohort study of 12,193 U.S. women evaluated for infertility between 1965 and…

ObjectiveTo evaluate the risk of ovarian cancer as related to underlying causes of infertility.DesignRetrospective observational cohort study.SettingFive large reproductive endocrinology practices.Patient(s)A total of 12,193 women evaluated…

A reduced risk of ovarian malignancy that is increasingly evident over time has been documented in several studies of oral contraceptive (OC) users and has been related to the presumed inhibitory effects of OCs on ovarian activity, especial…

Ovarian cysts are the fourth most common gynaecological cause for admission to hospital in England and Wales, with 14000 discharges annually. Little is known about their aetiology or distribution in the population. This report summarises th…

Clinical findings suggest a relationship between prostaglandins of the F2a group progesterone and dysmenorrhea. The menstrual flow of 5 dysmenorrhoic women aged 20-30 years was collected 2 cycles with and 2 cycles without local intrauterine…